AURKA and gastric cancer: This study evidences previously observed perturbations of the KRAS, ERBB2, EGFR, MET, PIK3CA, FGFR2 and AURKA genes in gastric cancer and suggests some of the targeted therapies approved or in clinical development would be of benefit to 11 of the 50 patients studied.